Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1375-1383

  Talieri, Maroulio ^a   Zoma, Marita ^a   Devetzi, Marina ^a   Scorilas, Andreas ^b   Ardavanis, Alexandros ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Brain tumors; Intracranial tumors; Kallikrein related peptidase 6; KLK6

Indexed keywords

CISPLATIN; KALLIKREIN 6; MESSENGER RNA;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACRANIAL TUMOR; MAJOR CLINICAL STUDY; MENINGIOMA; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84868147958     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0385-4     Document Type: Article

References (54)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6-29.
2. Wen PY, Kesari S. Malignant gliomas in adults. New Engl J Med. 2008;359:492-507.
3. Davis F, Malmer B, Aldape K, Barnholtz-Sloan JS, Bondy ML, Brannstrom Th, et al. Issues of diagnostic review in brain tumor studies: From the brain tumor epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2008;17:484-9.
4. Adamson C, Kanu OO, Mehta AI, Di CH, Lin N, Mattox AK, et al. Glioblastoma multiforme: A review of where we have been and where we are going. Expert Opin Investig Drugs. 2009;18:1061-83.
5. Lu Ch, Shervington A. Chemoresistance in gliomas. Mol Cell Biochem. 2008;312:71-80.
6. Arribas Alpuente L, Menendez Lopez A, Yaya Tur R. Glioblastoma: Changing expectations. Clin Transl Oncol. 2011;13(4):240-8.
7. Claus EB, Bondy ML, Schildkraut JM, Wiemels J, Wrensch M, Black PΜ. Epidemiology of intra-cranial meningioma. Neurosurgery. 2005;57:1088-95.
8. Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol. 2010;99:379-91.
9. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumor suppression. Nat Rev Cancer. 2007;7:800-8.
10. Borgono CA, Diamandis EP. The emerging roles of human kallikreins in cancer. Nat Rev Cancer. 2004;4:76-90.
11. Pampalakis G, Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta. 2007;1776:22-31.
12. Lu Y, Papagerakis P, Yamakoshi Y, Hu JCC, Bartlett JD, Simmer JP. Functions of KLK4 and MMP-20 in dental enamel formation. Biol Chem. 2008;389:695-700.
13. Scarisbrick IA, Limbo R, Vandell AG, Keegan M, Blaber SI, Blaber M, et al. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegenaration. Biol Chem. 2008;389:739-46.
14. Hollenberg MD, Oikonomopoulou K, Hansen KK, Saifeddine M, Ramachandran R, Diamandis EP. Kallikreins and proteinase-mediated signaling: Proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. Biol Chem. 2008;389:643-51.
15. Shaw JLV, Diamandis EP. A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology. Biol Chem. 2008;389:681-8.
16. Smith RS, Gao Jr L, Chao L, Chao J. Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. Biol Chem. 2008;389:725-30.
17. Sotiropoulou G, Pampalakis G, Diamandis EP. Functional roles of human kallikrein-related peptidases. J Biol Chem. 2009;284:32989-94.
18. Yousef GM, Tadaaki T. Diamandis EP (2003) Role of kallikrein enzymes in the central nervous system. Clin Chim Acta. 2003;329:1-8.
19. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: Applications in cancer. Cancer Lett. 2005;224:1-22.
20. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med. 1996;2:624-36.
21. Yamashiro K, Tsuruoka N, Kodama S, Tsujimoto M, Yamamura Y, Tanaka T, et al. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim Biophys Acta. 1997;1350(1):11-4.
22. Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, et al. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J Biol Chem. 1997;272:25135-42.
23. Yousef GM, Luo LY, Scherer SW, Sotiropoulou G, Diamandis EP. Molecular characterization of zyme/protease M/neurosine (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics. 1999;62:251-9.
24. Bernett MJ, Blaber SI, Scarisbrick IA, Dhanaraja P, Thompson SM, Blaber M. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem. 2002;277:24562-70.
25. Scarisbrick IA, Isackson PJ, Ciric B, Windebank AJ, Rodriguez M. MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J Comp Neurol. 2001;431:347-61.
26. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53:1423-32.
27. Tatebea Η, Watanabeb, Kasaia Τ, Mizunoa Τ, Nakagawaa Μ, Tanakab Μ, et al. Extracellular neurosin degrades α-synuclein in cultured cells. Neurosci Res. 2010;67:341-6.
28. Ashby EL, Kehoe PG, Love S. Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia. Brain Res. 2010;1363:1-10.
29. Scarisbrick IA, Blaber SI, Tingling JT, Rodriguez M, Blaber M, Christophi GP. Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J Neuroimmunol. 2006;178:167-76.
30. Hebb AL, Bhan V, Wishart AD, Moore CS, Robertson GS. Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis. Curr Drug Discov Technol. 2010;7(2):137-40.
31. Mavridis K, Scorilas A. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol. 2010;6:269-85.
32. Shan SJ, Scorilas A, Katsaros D, Diamandis EP. Transcriptional up-regulation of human tissue kallikrein 6 in ovarian cancer: Clinical and mechanistic aspects. Br J Cancer. 2007;96:362-72.
33. Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Inoue H, Nagahara H, et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res. 2005;11:2889-93.
34. Nagahara H, Mimori K, Utsunomiya T, Barnard GF, Ohira M, Hirakawa K, et al. Clinicopathologic and biological significance of KLK6 overexpression in human gastric cancer. Clin Cancer Res. 2005;11:6800-6.
35. Ruckert F, Hennig M, Petraki CD, Wehrum D, Distler M, Denz A, et al. Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. Br J Cancer. 2008;99(9):1484-92.
36. \Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, et al. Human kallikrein 6: A new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res. 2005;11(9):3320-5.
37. Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, Sotiropoulou G. A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to mesenchymal transition. Cancer Res. 2009;69(9):3779-87.
38. Petraki CD, Gregorakis AK, Papanastasiou PA, Karavana VN, Luo LY, Diamandis EP. Immunohistochemical localization of human kallikreins 6, 10, 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis. 2003;6(3):223-7.
39. Krenzer S, Peterziel H, Mauch C, Blaber SI, Blaber M, Angel P, et al. Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment. J Invest Dermatol. 2011;131:2281-8.
40. Ni X, Zhang W, Huabg KC, Wang Y, Ng SK, Mok SC, et al. Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer. 2004;91(4):725-31.
41. Klucky B, Mueller R, Vogt I, Teurich S, Hartenstein B, Breuhahn K, et al. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration and invasion. Cancer Res. 2007;67:8198-6.
42. Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, et al. Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochim Biophys Res Commun. 2003;307:948-55.
43. Chosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumor cells. Tumor Biol. 2004;25:193-9.
44. Bayes A, Tseklenis T, Ventura S, Vendrell J, Aviles FX, Sotiropoulou G. Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol Chem. 2004;385:517-24.
45. Scarisbrick IA, Epstein B, Cloud BA, Yoon H, Wu J, Renner DN, et al. Functional role of kallikrein 6 in regulating immune cell survival. PLoS One. 2011;6(3):1-11. e18376.
46. Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou K, Lah TT. Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res. 2009;29(8):3269-79.
47. Prezas P, Scorilas A, Yfanti Ch, Viktorov P, Agnanti N, Diamandis EP, et al. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. Biol Chem. 2006;387:1607-12.
48. Talieri M, Pappa E, Scorilas A, Devetzi M, Tsapralis N, Ardavanis A, et al. Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact. Tumor Biol. 2012. doi: 10.1007/s13277-012-0347-x.
49. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-8.
50. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252-9.
51. Petraki CD, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJ, Yousef GM, et al. The spectrum of human kallikrein6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem. 2001;49(11):1431-41.
52. Bettinger I, Thanos S, Paulus W. Microglia promote glioma migration. Acta Neuropathol. 2002;103:351-5.
53. Klein R, Roggendorf W. Increased microglia proliferation separates pilocytic astrocytomas from diffuge astrocytomas: A double labeling study. Acta Neuropathol. 2001;101:245-8.
54. Leenstra S, Das P, Troost D, Boer OJ, Bosch DA. Human malignant astrocytes express macrophage phenotype. J Neuroimmunol. 1995;56:17-25.